AAVantgarde Bio

AAVantgarde Bio is a clinical stage biotechnology company that is developing gene therapies for inherited retinal disorders.

The AAVantgarde cutting-edge gene therapy technology platforms are focused on solving the constraint of oversized gene delivery.

AAVantgarde was co-founded in 2021 by Professor Alberto Auricchio at TIGEM (Telethon Institute of Genetics and Medicine) and Telethon Foundation. The company is headquartered in Milan, Italy.


AAVantgarde has two proprietary, AAV-based large gene delivery platforms: one leveraging DNA recombination, named dual hybrid; and one protein trans-splicing, named AAV intein.


AAVantgarde is validating the platforms in two lead programs: Usher Syndrome Type 1 B associated retinitis pigmentosa (Usher1B), using dual hybrid; and Stargardt disease, using AAV intein.


AAVantgarde has raised €61M ($65.3M) in a Series A round on Jun 06, 2023. The round was co-led by Atlas Venture and Forbion, with participation from Longwood Fund, Sofinnova Partners and Fondazione Telethon.



  • Year founded: 2021
  • Funding Info: €61M ($65.3M) over 1 Round (Funding Type: Series A)
  • Yearly Revenue: NA
  • Employee Size: 2-10
  • Business Valuation: NA
  • City/Town: Milan
  • State: Lombardy
  • Country: Italy
Related businesses